article thumbnail

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Express Pharma

As the pharmaceutical industry targets $130 billion by 2030 (7) and the medical devices market is eyeing $ 50 billion by 2030 (8), incubators and innovation hubs will be instrumental in harnessing this potential, empowering entrepreneurs to lead the nation’s growth in these sectors. India, with 47 per cent of its 1.4

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

from 2023 to 2030. Simplified Communication and Coordination : Integrated CDMOs can improve cross-team coordination between research, development, and manufacturing, reducing the need for external hand-offs, technology transfer, and knowledge dissemination. .”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca announces $50bn US investment plans by 2030

Pharmaceutical Technology

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). It will also support our ambition to reach $80bn in revenue by 2030.” Credit: grandbrothers/Shutterstock.com. Give your business an edge with our leading industry insights.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.

article thumbnail

How ICH E6 (R3) is changing clinical trials

Pharmaceutical Technology

Integrated CDMS solutions also facilitate smoother communication and coordination between stakeholders, enabling faster, data-driven decision-making – all increasingly crucial for maintaining oversight and regulatory compliance. The updated ICH E6 (R3) guidelines introduce a range of critical changes aimed at modernizing clinical trials.

article thumbnail

STAT+: Generative AI is transforming radiology, and it’s only the beginning

STAT

By 2030, agreed a roomful of radiologists in Chicago this week, generative AI will be ubiquitous in their written work. 

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. LanKS via Shutterstock.